“…20,22,40,41,43,45 Like the pharmacological intervention studies, loss to follow-up and study withdrawal was common in the included studies. Some of the included nonpharmacological studies recruited solely glioma patients, 11,12,14,19,21,41,43,44 and others included multiple pathologies including ependymoma, 37,42 subependymoma, 42 medulloblastoma, 37 neuroblastoma, 37 meningioma, 13,15,17,18,20,22,38,39,42 craniopharyngioma, 40 metastasis 17,20,39 and non-Hodgkin lymphoma. 20 Like the studies evaluating pharmacological interventions, those evaluating nonpharmacological intervention included patients that had received varying treatments including surgery, radiotherapy and/or chemotherapy.…”